Breaking News Instant updates and real-time market news.

RMAX

RE/MAX Holdings

$39.05

1.03 (2.71%)

, RDFN

Redfin

$18.41

-0.05 (-0.27%)

09:25
03/19/19
03/19
09:25
03/19/19
09:25

RE/MAX, Redfin partnership mutually beneficial, says William Blair

The exclusive referral partnership announced last night by RE/MAX Holdings (RMAX) and Redfin (RDFN) should be mutually beneficial and makes a lot of sense strategically, William Blair analyst Stephen Sheldon tells investors in a research note. The arrangement appears to be a positive development for RE/MAX, and does not appear to have any notable downside, adds the analyst. He feels the partnership is a good sign for the company's overall market position, noting Redfin specifically approached RE/MAX for the arrangement, likely in part due to its leading brokerage position in Canada. Sheldon admits, however, that it is tough to predict any potential financial impact at this point. He has an Outperform rating on RE/MAX and Market Perform rating on Redfin.

RMAX

RE/MAX Holdings

$39.05

1.03 (2.71%)

RDFN

Redfin

$18.41

-0.05 (-0.27%)

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

RMAX RE/MAX Holdings
$39.05

1.03 (2.71%)

11/19/18
11/19/18
UPGRADE
Target $36

Overweight
Morgan Stanley sees RE/MAX as 'steadier' housing play, upgrades to Overweight
As previously reported, Morgan Stanley analyst Vikram Malhotra upgraded RE/MAX Holdings to Overweight from Equal Weight, noting that the stock is down 36% year-to-date as the housing market has cooled, like its housing-levered peers. However, he thinks the current valuation does not give much credit for its franchise attributes, telling investors that RE/MAX's agent-driven recurring revenue model makes it a steadier housing play. Additionally, the market seems to be undervaluing the company's new mortgage business, Motto, Malhotra contends. However, he lowered his price target on RE/MAX shares to $36 from $56.
12/31/18
PIPR
12/31/18
NO CHANGE
PIPR
Piper favors Fidelity National, RE/MAX amid slowing home sales
Existing home sales remained in a weak trend at down 4% year-over-year in November versus down 3% in October and down 2% in Q3, Piper Jaffray analyst Jason Deleeuw tells investors in a research note. The analyst believes the key drivers continue to be tight home inventories and increased discretion by home buyers after years of steady home price gains have reduced affordability. He continues to expect home sales trends to post low- to mid-single-digit declines for 2019. In this environment, Deleeuw's favorite real estate names are Fidelity National Financial (FNF) and RE/MAX Holdings (RMAX) since both have "catalysts/business models not as sensitive to sales volume trends." Fidelity National is the analyst's favorite real estate name given the potential earnings accretion from the pending Stewart (STC) acquisition that he believes is not factored much into the share price. Deleeuw also favors RE/MAX citing its "steady and high return business model that can sustain growth in multiple housing environments." Agent count and agent fees rather than volume drive the bulk of the company's franchise model economics, says Deleeuw.
01/24/19
COMP
01/24/19
INITIATION
COMP
Neutral
RE/MAX Holdings initiated with a Neutral at Compass Point
03/15/19
PIPR
03/15/19
NO CHANGE
Target $48
PIPR
Overweight
Piper remains bullish on shares of RE/MAX Holdings
After spending time with management, Piper Jaffray analyst Jason Deleeuw remains bullish on the RE/MAX Holdings stock story. The real estate brokerage space is experiencing significant disruption from an influx of capital and technology, but RE/MAX continues to have strong competitive positioning and durable growth, Deleeuw tells investors in a research note. He sees the company as an attractive small cap growth idea and reiterates an Overweight rating on the shares with a $48 price target.
RDFN Redfin
$18.41

-0.05 (-0.27%)

01/22/19
DADA
01/22/19
DOWNGRADE
Target $15.5
DADA
Underperform
Redfin downgraded to Underperform from Neutral at DA Davidson
DA Davidson analyst Tom White downgraded Redfin to Underperform from Neutral and lowered his price target to $15.50 from $17, saying that while the company offers a "longer-term disruption" to the traditional real estate market, it faces near-term headwinds on revenue and profitability. Specifically, the analyst points to Redfin's continued declined in listings shares where the company offers a 1% seller commission, a softening in the U.S. residential real estate market, and "uncertain ROI from incremental marketing spend". White also lowers his FY19 EPS to (54c) from (52c).
01/24/19
COMP
01/24/19
INITIATION
COMP
Buy
Redfin initiated with a Buy at Compass Point
Compass Point analyst Chris Gamaitoni initiated Redfin with a Buy.
02/04/19
SUSQ
02/04/19
NO CHANGE
SUSQ
Susquehanna makes case for Century Communities and Redfin to be acquired
Susquehanna analyst Jack Micenko laid out a case for why he thinks Pulte (PHM) should buy Century Communities (CCS) and why Amazon.com (AMZN) should buy Redfin (RDFN). The analyst feels Pulte is under-penetrated in the true entry-level segment of the market and Century could quickly fill the need in terms of both product type and geography. He believes Pulte could pay a roughly 40% premium to Century's current stock price and still see accretion from the deal. As for Amazon, he noted they have been more active around housing than many appreciate and he believes the data opportunity with Redfin is significant. He said Amazon could pay a roughly 60% premium to Redfin's current stock price. Micenko has a Neutral rating and $25 price target on Pulte while he does not have a rating on shares of Century Communities. Amazon is covered by analyst Shyam Patil, who has a Positive rating and $2,250 price target, and Micenko has a Positive rating and $19 price target on Redfin shares.
02/15/19
RBCM
02/15/19
NO CHANGE
Target $26
RBCM
Outperform
Redfin price target raised to $26 from $20 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Redfin to $26 and kept his Outperform rating after its Q4 earnings beat and Q1 guidance bracketing consensus. The analyst cites the management's confidence in the company's "mass marketing initiative" and "cautious" optimism for the housing market, which he expects to sustain FY19 revenue growth rate consistent with levels seen in FY18.

TODAY'S FREE FLY STORIES

MTG

MGIC Investment

$13.74

0.22 (1.63%)

06:48
10/22/19
10/22
06:48
10/22/19
06:48
Earnings
MGIC Investment reports Q3 adj. EPS 48c, consensus 42c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CIT

CIT Group

$45.65

1.36 (3.07%)

06:47
10/22/19
10/22
06:47
10/22/19
06:47
Earnings
CIT Group reports Q3 EPS $1.50, consensus $1.21 »

Reports Q3 revenue $454M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GPK

Graphic Packaging

$14.86

0.205 (1.40%)

06:44
10/22/19
10/22
06:44
10/22/19
06:44
Earnings
Graphic Packaging reports Q3 EPS 20c, consensus 19c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

06:44
10/22/19
10/22
06:44
10/22/19
06:44
Hot Stocks
Biogen soars 20% on plans to pursue Alzheimer's approval after FDA talks »

Shares of Biogen are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HLX

Helix Energy

$8.32

0.31 (3.87%)

06:43
10/22/19
10/22
06:43
10/22/19
06:43
Earnings
Helix Energy narrows FY19 revenue view to $730M-$760M from $700M-$760M »

Consensus is $749.91M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 14

    Nov

PNTG

The Pennant Group

$18.37

0.19 (1.05%)

06:43
10/22/19
10/22
06:43
10/22/19
06:43
Initiation
The Pennant Group initiated  »

The Pennant Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$32.28

0.57 (1.80%)

06:42
10/22/19
10/22
06:42
10/22/19
06:42
Earnings
Peoples Bancorp reports Q3 EPS 72c, consensus 70c »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 04

    Dec

  • 05

    Dec

ACRS

Aclaris Therapeutics

$1.40

-0.205 (-12.77%)

06:41
10/22/19
10/22
06:41
10/22/19
06:41
Upgrade
Aclaris Therapeutics rating change  »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

FITB

Fifth Third

$28.04

0.71 (2.60%)

06:40
10/22/19
10/22
06:40
10/22/19
06:40
Hot Stocks
Fifth Third sees Q4 NII down about 1% from Q3, NIM down 4-5bps »

Sees FY19 NII up about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

ARCH

Arch Coal

$78.98

-0.1 (-0.13%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Hot Stocks
Arch Coal backs FY19 total sales volume view 86.7- 92.1 tons »

"We are confident in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HAS

Hasbro

$120.11

-1.78 (-1.46%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Hot Stocks
Hasbro CEO says 'on track to deliver profitable revenue growth in 2019' »

"Hasbro remains on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

CVNA

Carvana

$77.23

3.42 (4.63%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Recommendations
Carvana analyst commentary  »

Carvana sold 15,239…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ARCH

Arch Coal

$78.98

-0.1 (-0.13%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Earnings
Arch Coal reports Q3 EPS $6.34, consensus $3.39 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ARES

Ares Management

$28.28

0.42 (1.51%)

, NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Hot Stocks
Ares Management sells ownership in Meade Pipeline to NextEra Energy Partners »

Ares Management (ARES)…

ARES

Ares Management

$28.28

0.42 (1.51%)

NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 31

    Oct

  • 04

    Dec

KOOL

Cesca Therapeutics

$5.31

-0.14 (-2.57%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Hot Stocks
Cesca Therapeutics forms JV with Healthbanks Biotech »

Cesca Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$223.57

3.52 (1.60%)

06:36
10/22/19
10/22
06:36
10/22/19
06:36
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen to offer access to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BIIB

Biogen

$223.57

3.52 (1.60%)

06:36
10/22/19
10/22
06:36
10/22/19
06:36
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen: Analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SNV

Synovus

$36.30

1.005 (2.85%)

06:35
10/22/19
10/22
06:35
10/22/19
06:35
Earnings
Synovus reports Q3 adjusted EPS 97c, consensus 99c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

, ESALY

Eisai

$0.00

(0.00%)

06:35
10/22/19
10/22
06:35
10/22/19
06:35
Hot Stocks
Biogen plans aducanumab BLA in early 2020 based on FDA talks »

Biogen (BIIB) and Eisai…

BIIB

Biogen

$223.57

3.52 (1.60%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FBC

Flagstar Bancorp

$38.72

0.39 (1.02%)

06:34
10/22/19
10/22
06:34
10/22/19
06:34
Earnings
Flagstar Bancorp reports Q3 EPS $1.11, consensus $1.04 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

, ESALY

Eisai

$0.00

(0.00%)

06:34
10/22/19
10/22
06:34
10/22/19
06:34
Hot Stocks
Breaking Hot Stocks news story on Biogen, Eisai »

Biogen plans aducanumab…

BIIB

Biogen

$223.57

3.52 (1.60%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UBS

UBS

$11.53

0.18 (1.59%)

06:33
10/22/19
10/22
06:33
10/22/19
06:33
Periodicals
UBS to address client overcharges in Singapore, Hong Kong, Reuters reports »

UBS is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Nov

FITB

Fifth Third

$28.04

0.71 (2.60%)

06:33
10/22/19
10/22
06:33
10/22/19
06:33
Earnings
Fifth Third reports Q3 EPS 71c with items, consensus 73c »

Reported results included…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

VRTX

Vertex

$183.73

7.49 (4.25%)

06:32
10/22/19
10/22
06:32
10/22/19
06:32
Recommendations
Vertex analyst commentary  »

Vertex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Mar

PHM

PulteGroup

$38.24

-0.08 (-0.21%)

06:32
10/22/19
10/22
06:32
10/22/19
06:32
Hot Stocks
PulteGroup reports Q3 unit backlog up 4% to 11,638 Homes »

Reports Q3 backlog value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.